NO323359B1 - Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. - Google Patents
Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. Download PDFInfo
- Publication number
- NO323359B1 NO323359B1 NO19983456A NO983456A NO323359B1 NO 323359 B1 NO323359 B1 NO 323359B1 NO 19983456 A NO19983456 A NO 19983456A NO 983456 A NO983456 A NO 983456A NO 323359 B1 NO323359 B1 NO 323359B1
- Authority
- NO
- Norway
- Prior art keywords
- bacteriophage
- phage
- bacterial
- antibody
- protein
- Prior art date
Links
- 241001515965 unidentified phage Species 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 5
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 230000001580 bacterial effect Effects 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 11
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 8
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 18
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 241000590002 Helicobacter pylori Species 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102400000368 Surface protein Human genes 0.000 claims description 6
- 229940037467 helicobacter pylori Drugs 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 206010065764 Mucosal infection Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 8
- 241000724791 Filamentous phage Species 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 241001524679 Escherichia virus M13 Species 0.000 abstract description 4
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 18
- 239000012634 fragment Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001590124 Helicobacter pylori 17874 Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710179596 Gene 3 protein Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600434A SE506771C2 (sv) | 1996-02-06 | 1996-02-06 | Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna |
| PCT/SE1997/000172 WO1997029185A1 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983456D0 NO983456D0 (no) | 1998-07-27 |
| NO983456L NO983456L (no) | 1998-10-06 |
| NO323359B1 true NO323359B1 (no) | 2007-04-10 |
Family
ID=20401289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983456A NO323359B1 (no) | 1996-02-06 | 1998-07-27 | Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0889955B1 (ko) |
| JP (1) | JP4015195B2 (ko) |
| KR (1) | KR100459638B1 (ko) |
| CN (1) | CN1125174C (ko) |
| AT (1) | ATE266091T1 (ko) |
| AU (1) | AU712767B2 (ko) |
| CA (1) | CA2244792A1 (ko) |
| DE (1) | DE69728975T2 (ko) |
| ES (1) | ES2221033T3 (ko) |
| HU (1) | HUP9901242A3 (ko) |
| IL (2) | IL125645A0 (ko) |
| NO (1) | NO323359B1 (ko) |
| NZ (1) | NZ331580A (ko) |
| RU (1) | RU2215032C2 (ko) |
| SE (1) | SE506771C2 (ko) |
| WO (1) | WO1997029185A1 (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140918A0 (en) | 1998-07-27 | 2002-02-10 | Genentech Inc | Improved transformation efficiency in phage display through modification of a coat protein |
| GB9908195D0 (en) * | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| DE60020366T2 (de) | 1999-06-14 | 2006-02-02 | Genentech Inc., San Francisco | Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage |
| AU2001278003A1 (en) | 2000-07-25 | 2002-02-05 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Bacteriophage having multiple host range |
| US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
| KR20040036176A (ko) * | 2002-10-23 | 2004-04-30 | (주)엘피스바이오텍 | 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법 |
| CN102296051B (zh) * | 2011-03-07 | 2014-09-17 | 江苏省农业科学院 | 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用 |
| RU2503716C1 (ru) * | 2012-09-27 | 2014-01-10 | Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) | ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ |
| GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
| CN106198523A (zh) * | 2016-07-06 | 2016-12-07 | 哈尔滨贝贝凯尔科技发展有限公司 | 微量元素检测试纸及其制备方法 |
| US20200271657A1 (en) | 2017-10-04 | 2020-08-27 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
| US11939592B2 (en) * | 2018-12-27 | 2024-03-26 | National University Corporation Tokai National Higher Education And Research System | Host bacterium specific nanoparticle |
| CN109679981A (zh) * | 2019-02-21 | 2019-04-26 | 武汉大学 | 一种甲酰基肽定向进化噬菌体及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| SE9304060D0 (sv) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
-
1996
- 1996-02-06 SE SE9600434A patent/SE506771C2/sv not_active IP Right Cessation
-
1997
- 1997-02-05 WO PCT/SE1997/000172 patent/WO1997029185A1/en active IP Right Grant
- 1997-02-05 IL IL12564597A patent/IL125645A0/xx active IP Right Grant
- 1997-02-05 EP EP97902815A patent/EP0889955B1/en not_active Expired - Lifetime
- 1997-02-05 RU RU98116471/13A patent/RU2215032C2/ru not_active IP Right Cessation
- 1997-02-05 HU HU9901242A patent/HUP9901242A3/hu unknown
- 1997-02-05 KR KR10-1998-0705761A patent/KR100459638B1/ko not_active IP Right Cessation
- 1997-02-05 CN CN97192116A patent/CN1125174C/zh not_active Expired - Fee Related
- 1997-02-05 ES ES97902815T patent/ES2221033T3/es not_active Expired - Lifetime
- 1997-02-05 AT AT97902815T patent/ATE266091T1/de not_active IP Right Cessation
- 1997-02-05 JP JP52844697A patent/JP4015195B2/ja not_active Expired - Fee Related
- 1997-02-05 AU AU16817/97A patent/AU712767B2/en not_active Ceased
- 1997-02-05 CA CA002244792A patent/CA2244792A1/en not_active Abandoned
- 1997-02-05 NZ NZ331580A patent/NZ331580A/en unknown
- 1997-02-05 DE DE69728975T patent/DE69728975T2/de not_active Expired - Fee Related
-
1998
- 1998-07-27 NO NO19983456A patent/NO323359B1/no unknown
- 1998-08-03 IL IL125645A patent/IL125645A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE266091T1 (de) | 2004-05-15 |
| NZ331580A (en) | 1999-09-29 |
| EP0889955B1 (en) | 2004-05-06 |
| DE69728975D1 (de) | 2004-06-09 |
| CN1210558A (zh) | 1999-03-10 |
| EP0889955A1 (en) | 1999-01-13 |
| HUP9901242A2 (hu) | 1999-07-28 |
| SE9600434D0 (sv) | 1996-02-06 |
| CN1125174C (zh) | 2003-10-22 |
| CA2244792A1 (en) | 1997-08-14 |
| AU712767B2 (en) | 1999-11-18 |
| AU1681797A (en) | 1997-08-28 |
| NO983456L (no) | 1998-10-06 |
| IL125645A0 (en) | 1999-04-11 |
| SE506771C2 (sv) | 1998-02-09 |
| ES2221033T3 (es) | 2004-12-16 |
| SE9600434L (sv) | 1997-08-07 |
| KR100459638B1 (ko) | 2005-02-24 |
| NO983456D0 (no) | 1998-07-27 |
| WO1997029185A1 (en) | 1997-08-14 |
| DE69728975T2 (de) | 2005-05-04 |
| JP2000505648A (ja) | 2000-05-16 |
| JP4015195B2 (ja) | 2007-11-28 |
| KR19990082041A (ko) | 1999-11-15 |
| IL125645A (en) | 2006-08-20 |
| RU2215032C2 (ru) | 2003-10-27 |
| HUP9901242A3 (en) | 2000-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112010965B (zh) | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 | |
| Cao et al. | Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth | |
| Steiner et al. | Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display | |
| EP0889955B1 (en) | Recombinant phages | |
| US20020044922A1 (en) | Recombinant phages | |
| Lester et al. | Characterization of H elicobacter pylori HP 0231 (DsbK): role in disulfide bond formation, redox homeostasis and production of H elicobacter cystein‐rich protein HcpE | |
| CN106008710B (zh) | 一种猪源性抗产肠毒素大肠杆菌K88 FaeG蛋白的单链抗体及其制备方法 | |
| Aikawa et al. | Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection | |
| Kwaśnikowski et al. | Multivalent display system on filamentous bacteriophage pVII minor coat protein | |
| AU661465B2 (en) | Pseudomonas peptide composition and method for producing the same | |
| Park et al. | Affinity maturation of natural antibody using a chain shuffling technique and the expression of recombinant antibodies in Escherichia coli | |
| Sabarth et al. | Identification of Helicobacter pylori surface proteins by selective proteinase K digestion and antibody phage display | |
| US6497874B1 (en) | Recombinant phages | |
| CN109503711B (zh) | 一种用于血凝方法检测pcv2病毒的双功能纳米抗体、编码基因及其应用 | |
| JP2005508395A (ja) | 炭疽菌毒素を検出および中和するための組換え抗体 | |
| CN104531730B (zh) | 产气荚膜梭菌α毒素人源化单链抗体8B | |
| MXPA06011501A (es) | Peptidos terapeuticos. | |
| Pokorny et al. | Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies | |
| CN108976289B (zh) | 用于预防和治疗肠致病大肠杆菌感染的肽段 | |
| AU5328599A (en) | Gastrointestinal bacterial antibody factories | |
| JP2007236237A (ja) | ベクターライブラリーの製造方法、人工ポリクローナル抗体の製造方法、及び医薬組成物の製造方法 | |
| Tout et al. | Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide | |
| Naylor | Development of a Dusky kob scFv gene phage display library for the discovery of antibodies to Brome mosaic virus-a proxy for a novel, emerging fish pathogen | |
| Del Giudice et al. | VirJ is a Brucella virulence factor involved in the secretion of Type IV secreted substrates Mariela Giselda Del Giudice1, Peter Hans Döhmer1, Juan Manuel Spera1, Fernando Tomás Laporte1, María Inés Marchesini1, Cecilia Czibener1* and Juan Esteban Ugalde1 | |
| Cappelletti et al. | Structure-Function Analysis of the HrpB2-HrcU Interaction in the |